Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent trials have studied higher dosages of omega-3 fatty acids, reporting a cardiovascular benefit in 2 trials of purified EPA. 10,11”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [11]
In the citing paper
“O3CA lowered non-HDL-C by 6% and apo B by 2%, 41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“With regard to O3CA, the 2-g/d dose examined in the ESPRIT trial (Epanova Combined with a Statin in Patients with Hypertriglyceridemia to Reduce Non-HDL Cholesterol; ≈1.5 g/d EPA+DHA) reduced triglycerides by 9% versus 15% with 4 g/d.41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“High‐dose eicosapentaenoic ethyl ester combined with baseline statins can lead to a remarkable decline in first and recurrent events in high‐risk patients with hypertriglyceridemia. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
In the citing paper
“Conversely, patients with hypertriglyceridemia treated with a medium‐to‐high dose of icosapent ethyl were less likely to develop ischemic events, including CVD death. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
126 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Self-citationEffects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Cited by
Items 701–800 of 1,052
Ambrosy, A. P., Yang, J., Sung, S. H., Allen, A. R., Fitzpatrick, J. K., Rana, J. S., Wagner, J., Philip, S., Abrahamson, D., Granowitz, C., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020377 · Cited by 32
Self-citationMichaeloudes, C., Christodoulides, S., Christodoulou, P., Kyriakou, T.-C., Patrikios, I. S., & Stephanou, A. (2023) · Nutrients · doi:10.3390/nu15224830 · Cited by 41
Sherratt, S. C. R., Libby, P., Dawoud, H., Bhatt, D. L., & Mason, R. P. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.034076 · Cited by 34
Self-citationFunctional Lipids and Cardiovascular Disease Reduction: A Concise Review
Omachi, D. O., Aryee, A. N. A., & Onuh, J. O. (2024) · Nutrients · doi:10.3390/nu16152453 · Cited by 40
von Schacky, C. (2020) · Proceedings of The Nutrition Society · doi:10.1017/s0029665120006989 · Cited by 41
Nelson, A. J., Navar, A. M., Mulder, H., Wojdyla, D., Philip, S., Granowitz, C., Peterson, E. D., & Pagidipati, N. J. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.07.005 · Cited by 32
Self-citationCardoso, R. N., Generoso, G., Staniak, H. L., Foppa, M., Duncan, B. B., Pereira, A. C., Blaha, M. J., Blankstein, R., Nasir, K., Benseñor, I. M., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.07.003 · Cited by 33
Wang, Y., Han, S., Qin, H., Zheng, H., Jiang, B., Cao, Y., Gao, Y., Guan, L., Jia, Q., Jiang, Y., et al. (2020) · Stroke and Vascular Neurology · doi:10.1136/svn-2020-000385 · Cited by 34
Aldoori, J., Cockbain, A. J., Toogood, G. J., & Hull, M. A. (2022) · Gut · doi:10.1136/gutjnl-2021-326362 · Cited by 35
Estándares SEA 2022 para el control global del riesgo cardiovascular
Mostaza, J. M., Pintó, X., Armario, P., Masana, L., Real, J. T., Valdivielso, P., Arrobas-Velilla, T., Baeza‐Trinidad, R., Calmarza, P., Cebollada, J., et al. (2022) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.11.003 · Cited by 70
Paragh, G., Németh, Á., Harangi, M., Banach, M., & Fülöp, P. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01631-z · Cited by 38
Etiology and Management of Dyslipidemia in Patients With Cancer
de Jesus, M., Mohammed, T. J., Singh, M., Tiu, J. G., & Kim, A. S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.892335 · Cited by 43
Li, J., Dou, K., Zhou, Z., Zhao, D. H., Ye, P., Zhao, J., & Guo, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1069992 · Cited by 40
A Revolution in Omega-3 Fatty Acid Research
Bhatt, D. L., Budoff, M. J., & Mason, R. P. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.005 · Cited by 38
Self-citationZobel, E. H., Wretlind, A., Ripa, R. S., Rotbain Curovic, V., von Scholten, B. J., Suvitaival, T., Hansen, T. W., Kjær, A., Legido-Quigley, C., & Rossing, P. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002395 · Cited by 31
“…or secondary to weight loss or improved glycemic control following liraglutide treat-ment, an active comparator should have been included (ie, insulin as a comparator for liraglutides effect on glycemic control or diet-induced weight loss as a comparator for liraglutides effect on body weight).”
Selvaraj, S., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Juliano, R. A., Jiao, L., Tardif, J., Ballantyne, C. M., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024999 · Cited by 31
Self-citationCurrent knowledge of the implication of lipid mediators in psoriasis
Simard, M., Morin, S., Ridha, Z., & Pouliot, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961107 · Cited by 32
Ballard‐Hernandez, J., & Sall, J. (2023) · Nursing Clinics of North America · doi:10.1016/j.cnur.2023.05.002 · Cited by 53
Drug Therapy of Dyslipidemia in the Elderly
Yandrapalli, S., Gupta, S., Andries, G., Cooper, H. A., & Aronow, W. S. (2019) · Drugs & Aging · doi:10.1007/s40266-018-00632-x · Cited by 32
Statistical Appraisal of 6 Recent Clinical Trials in Cardiology
Pocock, S., & Collier, T. J. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.484 · Cited by 32
Pediatric Dyslipidemia—Beyond Familial Hypercholesterolemia
Lazarte, J., & Hegele, R. A. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.03.020 · Cited by 32
Cao, Y., Zhang, H., Jin, J., Liu, H., Zhang, Y., Xu, R., Gao, Y., Guo, Y., Zhu, C., Hua, Q., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000746 · Cited by 32
Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review
Toth, P. P., Shah, P. K., & Lepor, N. E. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100086 · Cited by 37
Yeung, J., Adili, R., Yamaguchi, A. A., Freedman, C. J., Chen, A., Shami, R., Das, A., Holman, T. R., & Holinstat, M. A. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002493 · Cited by 33
Limonte, C. P., Zelnick, L. R., RUZINSKI, J. T., Hoofnagle, A. N., Thadhani, R., Melamed, M. L., Lee, I.-M. M., Buring, J. E., Sesso, H. D., Manson, J. E., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05300-7 · Cited by 34
Cardiovascular effects of omega-3 fatty acids: Hope or hype?
Jo, S., Han, S. H., Kim, S., Eckel, R. H., & Koh, K. K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.02.014 · Cited by 34
Morieri, M. L., Perrone, V., Veronesi, C., Esposti, L. D., Andretta, M., Plebani, M., Fadini, G. P., de Kreutzenberg, S. V., & Avogaro, A. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01338-y · Cited by 38
Lamon‐Fava, S., Liu, M., Dunlop, B. W., Kinkead, B. L., Schettler, P. J., Felger, J. C., Ziegler, T. R., D, M. F. M., Mischoulon, D., & Rapaport, M. H. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01527-7 · Cited by 39
Omega-3 fatty acids and individual variability in plasma triglyceride response: A mini-review
Rundblad, A., Sandoval, V., Holven, K. B., Ordovás, J. M., & Ulven, S. M. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102730 · Cited by 37
European guidelines for the treatment of dyslipidaemias: New concepts and future challenges
Pirillo, A., Casula, M., & Catapano, A. L. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106936 · Cited by 42
Ademi, Z., Ofori-Asenso, R., Zomer, E., Owen, A., & Liew, D. (2021) · European Journal of Preventive Cardiology · doi:10.1177/2047487319896648 · Cited by 30
Lipid management for cardiovascular risk reduction in type 1 diabetes
Tell, S., Nadeau, K. J., & Eckel, R. H. (2020) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000551 · Cited by 30
Lipid-Modifying Therapies and Stroke Prevention
Hackam, D. G., & Hegele, R. A. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01197-4 · Cited by 37
Resolvin T4 enhances macrophage cholesterol efflux to reduce vascular disease
Walker, M. E., Matteis, R. D., Perretti, M., & Dalli, J. (2024) · Nature Communications · doi:10.1038/s41467-024-44868-1 · Cited by 32
Rios, F. J. O., Ciuceis, C. D., Georgiopoulos, G. A., Lazaridis, A. A., Nosalski, R., Pavlidis, G., Tual‐Chalot, S., Rosei, C. A., Camargo, L. L., Dąbrowska, E., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.123.22483 · Cited by 37
Lu, J., Liu, R., Ren, H., Wang, S., Hu, C., Shi, Z., Li, M., Liu, W., Wan, Q., Su, Q., et al. (2024) · Med · doi:10.1016/j.medj.2024.07.024 · Cited by 39
Lan, N. S. R., Dwivedi, G., Fegan, P. G., Game, F. L., & Hamilton, E. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02527-1 · Cited by 42
Liu, S., Faitg, J., Tissot, C., Konstantopoulos, D., Laws, R., Bourdier, G., Andreux, P. A., Davey, T., Gallart‐Ayala, H., Ivanišević, J., et al. (2025) · iScience · doi:10.1016/j.isci.2025.111814 · Cited by 48
Chapman, M. J., Packard, C. J., Björnson, E., Ginsberg, H. N., & Borén, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120529 · Cited by 39
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 52
Self-citationFeingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 50
Polyunsaturated fatty acids and sepsis
Das, U. N. (2019) · Nutrition · doi:10.1016/j.nut.2019.02.016 · Cited by 31
Gonna, H., & Ray, K. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13691 · Cited by 33
Triglycerides and endothelial function: molecular biology to clinical perspective
Kajikawa, M., & Higashi, Y. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000630 · Cited by 33
Toko, H., Morita, H., Katakura, M., Hashimoto, M., Ko, T., Bujo, S., Adachi, Y., Ueda, K., Murakami, H., Ishizuka, M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72686-0 · Cited by 32
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Dyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly
LUCCHI, T. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07347-x · Cited by 42
Dyslipidemia in Patients with Kidney Disease
Thobani, A., & Jacobson, T. A. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.008 · Cited by 36
Self-citationOmega‐3 fatty acids for the prevention of atherosclerotic cardiovascular disease
Barry, A. R., & Dixon, D. L. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2615 · Cited by 36
Zhai, Z., Niu, K., Liu, H., Lin, C., Tu, Y., Liu, Y., Cai, L., Kexian, O., & Liu, J. (2021) · Journal of Food Science · doi:10.1111/1750-3841.15951 · Cited by 32
Thambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 51
Chen, H., Tong, H., Shen, W., Montilla, T., Case, M., Almond, M. A., Wells, H., Alexis, N. E., Peden, D. B., Rappold, A. G., et al. (2022) · Environment International · doi:10.1016/j.envint.2022.107407 · Cited by 31
Deora, N., & Venkatraman, K. (2022) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2022.100675 · Cited by 48
Witt, A., Mateska, I., Palladini, A., Sinha, A. N., Wölk, M., Harauma, A., Bechmann, N., Pamporaki, C., Dahl, A., Rothe, M., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf6710 · Cited by 32
Wang, H., Liu, W., Zailani, H., Yang, C., Chen, T., Chang, C., Tsai, I., Yang, C., & Su, K. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.03.019 · Cited by 36
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia
Aseem Basha, M. (2019) · Journal of the Practice of Cardiovascular Sciences · doi:10.4103/jpcs.jpcs_16_19 · Cited by 36
Joshi, R., Wannamethee, S. G., Engmann, J., Gaunt, T. R., Lawlor, D. A., Price, J. F., Papacosta, O., Shah, T., Tillin, T., Chaturvedi, N., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319899621 · Cited by 31
Zelniker, T. A., Morrow, D. A., Scirica, B. M., Furtado, J. D., Guo, J., Mozaffarian, D., Sabatine, M. S., & O’Donoghue, M. L. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.017401 · Cited by 26
“5,30 However, this was a secondary safety end point, and differences in risk of atrial fibrillation have not been re-ported in prior trials of n-3 PUFA supplements, whereas observational studies of fish consumption have shown inverse associations with risk of atrial fibrillation.”
The diverse roles of macrophages in metabolic inflammation and its resolution
Ray, A. G., Odum, O., Wiseman, D., & Weinstock, A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1147434 · Cited by 34
Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial
Sayah, N., Bhatt, D. L., Miller, M. J., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Jiao, L., Pineda, A. L., Doyle, R. T., Tardif, J., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad889 · Cited by 34
Self-citationOmega-3 PUFAs slow organ aging through promoting energy metabolism
Xiong, Y., Li, X., Liu, J., Luo, P., Zhang, H., Zhou, H., Ling, X., Zhang, M., Ye, L., Chen, Q., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107384 · Cited by 31
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S)
Strandberg, T. E., Kovanen, P. T., Lloyd‐Jones, D. M., Raal, F. J., Santos, R. D., & Watts, G. F. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02089-0 · Cited by 30
The NLRP3-inflammasome inhibitor MCC950 improves cardiac function in a HFpEF mouse model
Li, S., Withaar, C., Gonçalves‐Rodrigues, P., Zijlstra, S. N., de Boer, R. A., Silljé, H. H. W., & Meems, L. M. G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117711 · Cited by 39
Muro, F. M. D., Vogel, B., Sartori, S., Bay, B., Oliva, A., Feng, Y., Krishnan, P., Sweeny, J. M., Gitto, M., Smith, K. F., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf112 · Cited by 36
Self-citationAwoyemi, A., Trøseid, M., Arnesen, H., Solheim, S., & Seljeflot, I. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.05.004 · Cited by 34
Omega-3 Polyunsaturated Fatty Acids and Stroke Burden
Ueno, Y., Miyamoto, N., Yamashiro, K., Tanaka, R., & Hattori, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225549 · Cited by 33
Farooq, M. A., Gaertner, S., Amoura, L., Niazi, Z. R., Park, S., Qureshi, A. W., Oak, M., Toti, F., Schini‐Kerth, V. B., & Auger, C. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113749 · Cited by 37
Ramos‐Sono, D., Laureano, R., Rueda, D., Gilman, R. H., Rosa, A. L., Ruiz, J., León, R., Sheen, P., & Zimic, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241067 · Cited by 29
Triglycerides and Atherosclerosis
Toth, P. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.058 · Cited by 32
A new phenotypic classification system for dyslipidemias based on the standard lipid panel
Sampson, M. L., Ballout, R. A., Soffer, D. E., Wolska, A. T., Wilson, S. R., Meeusen, J. W., Donato, L. J., Fatica, E. M., Otvos, J. D., Brinton, E. A., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01585-8 · Cited by 37
Self-citationGoldberg, R. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.011 · Cited by 34
Safety of Statins and Nonstatins for Treatment of Dyslipidemia
Newman, C. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.01.004 · Cited by 39
Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies
King, R. W., Canonico, M. E., Bonaca, M. P., & Hess, C. N. (2022) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2022.100513 · Cited by 36
Olshansky, B., Bhatt, D. L., Miller, M., Steg, P. G., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.121.026756 · Cited by 29
Self-citationSorokin, A. V., Arnardottir, H. H., Svirydava, M., Ng, Q., Baumer, Y., Berg, A., Pantoja, C. J., Florida, E. M., Teague, H., Yang, Z., et al. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109348 · Cited by 35
Trends in epidemiology of dyslipidemias in India
Sharma, S., Gaur, K., & Gupta, R. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2023.11.266 · Cited by 52
Soohoo, M., Moradi, H., Obi, Y., Kovesdy, C. P., Kalantar‐Zadeh, K., & Streja, E. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.08.001 · Cited by 30
[Incisional hernia after surgery for abdominal aortic aneurysm].
Augestad, K. M., Wilsgaard, T., & Solberg, S. K. (2002) · Tidsskrift for Den Norske Laegeforening · Cited by 41
Sea Change for Marine Omega-3s
O'Keefe, E. L., Harris, W. S., DiNicolantonio, J. J., Elagizi, A., Milani, R. V., Lavie, C. J., & O'Keefe, J. H. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.04.027 · Cited by 28
Luo, Y., & Peng, D. (2023) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484231189597 · Cited by 32
Sidorkiewicz, M. (2024) · Nutrients · doi:10.3390/nu16223937 · Cited by 32
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review
Zimodro, J. M., Rizzo, M., & Gouni‐Berthold, I. (2025) · Pharmaceuticals · doi:10.3390/ph18020147 · Cited by 32
Aaseth, E., Halvorsen, S., Helseth, R., & Gravning, J. A. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf104 · Cited by 32
A Perspective on Targeting Inflammation and Cytokine Actions in Atherosclerosis
Chan, Y., & Ramji, D. P. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0301 · Cited by 31
Current Status of Dyslipidemia Treatment for Stroke Prevention
Aradine, E., Hou, Y., Cronin, C. A., & Chaturvedi, S. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01052-4 · Cited by 30
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
Selvaraj, S., Claggett, B. L., Packer, M., Zannad, F. M., Anand, I. S., Pieske, B. M., Zhao, Z., Shi, V. C., Lefkowitz, M. P., McMurray, J. J. V., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022069 · Cited by 30
Barbarawi, M., Lakshman, H. G., Barbarawi, O., Al‐Abdouh, A., kasasbeh, M. A., Djoussé, L., & Manson, J. E. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106458 · Cited by 33
Jo, S., Nam, H., Lee, J., Park, S., Lee, J., & Kyoung, D. (2021) · Diabetes Care · doi:10.2337/dc20-1533 · Cited by 30
Comprehensive Assessment of High-Risk Plaques by Dual-Modal Imaging Catheter in Coronary Artery
Kim, S., Nam, H. S., Lee, M. W., Kim, H. J., Kang, W. J., Song, J. W., Han, J., Kang, D. O., Oh, W., Yoo, H., et al. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.10.005 · Cited by 30
Weintraub, W. S., Bhatt, D. L., Zhang, Z., Dolman, S. F., Boden, W. E., Bress, A. P., King, J. B., Bellows, B. K., Tajeu, G. S., Derington, C. G., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.48172 · Cited by 29
Self-citationDiet and Nutrition in Peripheral Artery Disease: A Systematic Review
Wan, D., Li, V., Banfield, L. E., Azab, S. M., de Souza, R. J., & Anand, S. S. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.01.021 · Cited by 32
Kim, K., Hong, S., Han, K., & Park, C. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155327 · Cited by 33
Zou, L., Zhang, Y., Cheraga, N., Abodunrin, O. D., Qu, K.-Y., Qiao, L., Ma, Y., Chen, L., & Huang, N. (2023) · Talanta · doi:10.1016/j.talanta.2023.124772 · Cited by 31
Drexel, H., Tamargo, J. L., Kaski, J. C., Lewis, B. S., Saely, C. H., Fraunberger, P., Dobrev, D., Komiyama, M., PLATTNER, T., Agewall, S., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad044 · Cited by 34
Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer’s Disease?1
Kuhn, A. J., & Raskatov, J. A. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191201 · Cited by 38
The role of biofactors in the prevention and treatment of age‐related diseases
Frank, J., Kisters, K., Stirban, O. A., Obeid, R., Lorkowski, S., Wallert, M., Egert, S., Podszun, M. C., Eckert, G. P., Pettersen, J. A., et al. (2021) · BioFactors · doi:10.1002/biof.1728 · Cited by 30
Lee, H., Schwamm, L. H., Sansing, L. H., Kamel, H., de Havenon, A., Turner, A. C., Sheth, K. N., Krishnaswamy, S., Brandt, C., Zhao, H., et al. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01120-w · Cited by 36
The sphingosine-1-phosphate receptor 1 mediates the atheroprotective effect of eicosapentaenoic acid
Zhou, T., Cheng, J., He, S., Zhang, C., Gao, M., Zhang, L., Sun, J., Zhu, Y., & Ai, D. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01070-3 · Cited by 29
Zac‐Varghese, S., Mark, P. B., Bain, S. C., Banerjee, D., Chowdhury, T. A., Dasgupta, I., De, P., Fogarty, D. G., Frankel, A., Goldet, G., et al. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03664-1 · Cited by 28
Seth, J., Sharma, S., Leong, C. J., & Rabkin, S. W. (2024) · Antioxidants · doi:10.3390/antiox13080955 · Cited by 33
Metadata
- Authors
- Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); FACT (French Alliance for Cardiovascular Trials), Département Hospitalo-Universitaire FIRE (Fibrose, Inflammation, and Remodeling), Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Université Paris-Diderot, INSERM Unité 1148, Paris (P.G.S.); National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the Department of Medicine, University of Maryland...
- University of Maryland, Baltimore (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 11-22
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899669642
- Cited by
- 3,317
- References
- 47
- Citations by year
- 2026: 327 · 2025: 354 · 2024: 377 · 2023: 430 · 2022: 427 · 2021: 481 · 2020: 518 · 2019: 362
- FWCI
- 286.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amarin
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- icosapent ethyl, eicosapentaenoic acid ethyl ester, hypertriglyceridemia, cardiovascular risk reduction, ischemic events, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, unstable angina, statin therapy, omega-3 fatty acids, secondary prevention, triglyceride-lowering therapy, LDL cholesterol, diabetes mellitus
- MeSH terms
- Aged, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.